Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop
tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as
bevacizumab, can block cancer growth in different ways. Some block the ability of cancer
cells to grow and spread. Others find cancer cells and help kill them or deliver
cancer-killing substances to them. It is not yet known whether paclitaxel works better with
or without bevacizumab in treating breast cancer.
PURPOSE: This randomized phase III trial is to see if paclitaxel works better with or without
bevacizumab in treating patients who have locally recurrent or metastatic breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Eastern Cooperative Oncology Group
Collaborators:
National Cancer Institute (NCI) NCIC Clinical Trials Group North Central Cancer Treatment Group NSABP Foundation Inc